The clinical impact of continuing to prescribe antiretroviral therapy in patients with advanced AIDS who manifest no virologic or immunologic benefit. par David A Wohl, Michelle A Kendall, Judith Feinberg, Beverly Alston-Smith, Susan Owens, Suzette Chafey, Michael Marco, Sharon Maxwell, Constance Benson, Philip Keiser, Charles van der Horst, Mark A Jacobson, A5030 Study Team

Accéder au texte intégral

Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial. par Shahin Lockman, Michael Hughes, Fred Sawe, Yu Zheng, James McIntyre, Tsungai Chipato, Aida Asmelash, Mohammed Rassool, Sylvester Kimaiyo, Douglas Shaffer, Mina Hosseinipour, Lerato Mohapi, Francis Ssali, Margret Chibowa, Farida Amod, Elias Halvas, Evelyn Hogg, Beverly Alston-Smith, Laura Smith, Robert Schooley, John Mellors, Judith Currier, OCTANE (Optimal Combination Therapy After Nevirapine Exposure) ACTG A5208/OCTANE Study Team

Accéder au texte intégral

Successful recruitment of a multi-site international randomized placebo-controlled trial in people with HIV with attention to diversity of race and ethnicity: critical role of cent... par Kathleen V. Fitch, Emma M. Kileel, Sara E. Looby, Markella V. Zanni, Laura R. Sanchez, Carl J. Fichtenbaum, Edgar T. Overton, Carlos Malvestutto, Judith A. Aberg, Karin L. Klingman, Beverly Alston-Smith, Judith Lavelle, Anne Rancourt, Sharlaa Badal-Faesen, Sandra Wagner Cardoso, Anchalee Avihingsanon, Sandesh Patil, Craig A. Sponseller, Kathleen Melbourne, Heather J. Ribaudo, Katharine Cooper-Arnold, Patrice Desvigne-Nickens, Udo Hoffmann, Pamela S. Douglas, Steven K. Grinspoon, on behalf of the REPRIEVE Investigators

Accéder au texte intégral